Drug Activity in Cancer Models and Clinical Trials
Author Information
Author(s): Johnson J I, Decker S, Zaharevitz D, Rubinstein L V, Venditti J M, Schepartz S, Kalyandrug S, Christian M, Arbuck S, Hollingshead M, Sausville E A
Primary Institution: Developmental Therapeutics Program, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute
Hypothesis
Does drug activity in preclinical models correlate with clinical trial outcomes?
Conclusion
The study found that in vivo activity in preclinical models does not closely correlate with clinical results, but certain predictors can indicate potential success in clinical trials.
Supporting Evidence
- In vivo activity did not closely correlate with clinical results for many agents.
- Hollow fibre activity was a better predictor of xenograft activity than other methods.
- 56% of compounds with high potency in cell line screens were active in multiple hollow fibres.
Takeaway
Scientists tested many cancer drugs in lab models and found that some predictions about how well they work in people were not accurate, but some tests helped identify promising drugs.
Methodology
The study analyzed the activity of 39 agents in preclinical models and their correlation with Phase II clinical trial results, as well as the predictive value of hollow fibre assays.
Limitations
The correlation between preclinical and clinical results was not strong, indicating limitations in the predictive power of current models.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website